Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
ViiV’s Vocabria-Rekambys Combo Nets 50% Growth: Japan President
ViiV Healthcare’s injectable combo therapy of Vocabria (cabotegravir) and Rekambys (rilpivirine) has racked up year-on-year growth of roughly 50% in Japan, illustrating strong demand for a long-acting treatment option for HIV, local president Motoi Muraki revealed. Speaking at a press…
To read the full story
Related Article
BUSINESS
- Kissei Slashes Tavneos Sales Forecast after Safety, Data Concerns
August 3, 2026
- Forxiga Exit Weighs on Ono’s Japan Sales, but Boosts Profit
August 3, 2026
- Bayer, JFCR Ink Strategic Oncology R&D Partnership
August 3, 2026
- CSL Debuts Higher-Dose Hizentra Prefilled Syringe in Japan
August 3, 2026
- Taisho Bags Japan Rights to Kaigene’s FcRn Inhibitor KG006
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…